Quintiles-Invested Samsung Biologics Proceeds On Schedule
• By PharmAsia News
SEOUL - South Korea's largest conglomerate Samsung Group announced April 22 the CEO and the company name of a joint venture with Quintiles Transnational Corp. making inroads into the biosimilar and biopharmaceutical business
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.